Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention.
Tuma
Rabiya
R
D000236:Adenoma / Q000188:drug therapy* / Q000517:prevention & control; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002319:Cardiovascular System / Q000187:drug effects; D000068579:Celecoxib; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000517:prevention & control*; D004334:Drug Administration Schedule; D000518:Eflornithine / Q000008:administration & dosage; D006801:Humans; D054547:National Cancer Institute (U.S.); D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011720:Pyrazoles / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000008:administration & dosage; D013467:Sulindac / Q000008:administration & dosage; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011720:Pyrazoles; D013449:Sulfonamides; D013467:Sulindac; D000068579:Celecoxib; D000518:Eflornithine